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1012-103 Blood Pressure Changes Do Not Influence the 
Beneficial Effects of Carvedilol Compared to Metoprolol 
in the Patients With Heart Failure: Results From COMET 
(Carvedilol or Metoprolol European Trial)
Marco Metra, Andrea Di Lenarda, Peter Hanrath, Michel Komajda, Beatrix Lutiger, John 
G. Cleland, Willem J. Remme, Armin Scherhag, Andrew Charlesworth, Karl Swedberg, 
Christian Torp-Pedersen, For the COMET investigators, University of Brescia, Brescia, 
Italy, National Heart and Lung Institute, London, United Kingdom
Background: The Carvedilol or Metoprolol European Trial (COMET) has shown a reduc-
tion in all-cause mortality with carvedilol, compared with metoprolol, in 3029 patients with
chronic heart failure (RR 0.83, 95%CI, 0.74-0.93, p=0.0017). The potenital influence on
this difference of effects on blood pressure (BP) is unknown.
Methods: We have related the effects on long-term mortality of baseline BP and its early
changes (∆) in COMET. Baseline analyses are presented for the intent to treat popula-
tion. ∆BP analyses are on treatment.
Results: At the end of the uptitration phase, 4 months after randomization, mean systolic
BP (SBP) declined from baseline by 3.8 + 17.4 mm Hg in the carvedilol group and 2.0 +
17.7 mm Hg in the metoprolol group (p = 0.01). Patients on carvedilol maintained a signif-
icantly lower mean SBP at most visits and also had a lower mean diastolic BP (DBP) at 4,
8, 16, 32, 44 and 52 months. Among the 2589 patients reassessed at 4 months, ∆SBP <
-3 mm Hg (median value) was found in 685/1291 (53%) patients on carvedilol and in 617/
1298 (48%) on metoprolol. Compared with the others, the patients with a > -3 mm Hg
∆SBP had a higher baseline SBP (133+19 versus 121+17 mm Hg, p<0.001) and DBP
(79+11 versus 76+10 mm Hg, p<0.001) with an higher prevalence of ischemic heart dis-
ease (54% versus 48%, p=0.002) and a lower prevalence of idiopathic cardiomyopathy
(43% versus 49%; p=0.001) and diabetes (21% versus 26%; p=0.002). There were 409/
1302 deaths (31%) in the patients with a ∆SBP > -3 mm Hg and 400/1287 (31%) in the
others. Mortality was reduced with carvedilol, compared to metoprolol, both in the
patients with ∆SBP > -3 mm Hg (28% versus 36%; RR, 0.76, 95% CI, 0.62-0.92;
p=0.0049) and in the others (28% versus 34%; RR, 0.79; 95% CI, 0.65-0.97; p=0.0229).
No interaction between the effect on mortality of carvedilol, compared to metoprolol, and
the ∆SBP was found (RR 1.05; 95% CI, 0.80-1.39). By multivariate analysis, a SBP >120
mmHg at baseline was associated with a lower mortality (RR, 0.72; 95% CI, 0.63-0.83;
p<0.0001) while ∆SBP was not significant.
Conclusion: Carvedilol reduces mortality compared to metoprolol irrespective of BP
lowering. A higher baseline SBP is associated with a lower mortality risk.
1012-104 Safety of Beta-Blockers in Patients With Heart Failure 
and Renal Insufficiency: Data From IMPACT-HF
Adrian F. Hernandez, Wendy A. Gattis, Jyotsna Garg, Alan Chu, A. Bleakley Chandler, 
Mihai Gheorghiade, Christopher M. O'Connor, Duke Clinical Research Institute, Durham, 
NC
Background: Renal insufficiency is a significant predictor of poor outcomes in heart fail-
ure (HF) patients. To date, little is known about the safety of beta-blockers (BB) in heart
failure patients with renal insufficiency because clinical trials of BB excluded patients with
significant renal disease.
Methods: The IMPACT-HF study was conducted in patients with systolic dysfunction
admitted for worsening chronic HF symptoms. The trial randomized patients to in-hospital
initiation of carvedilol compared to the standard practice of post discharge (>2 weeks) BB
initiation. A registry was conducted concurrently with the main trial to collect data on all
HF hospitalizations. The IMPACT-HF trial and registry databases were combined and ret-
rospectively analyzed to determine if the use of BB in HF patients with moderate (esti-
mated GFR 30-60 mL/min per 1.73 m2) or severe (<30 mL/min per 1.73 m2) renal
insufficiency had a higher rate of death or rehospitalization within 60 days than patients
without beta-blockers. An unadjusted analysis was performed, as well as a model
adjusted for age, systolic blood pressure at baseline and nitrates prescribed at admission
and prior HF hospitalizations.
Results: Overall, 908 pts were enrolled in the IMPACT-HF trial and registry. In the total
population, 270 (29.7%) pts had severe renal insufficiency and 308 (33.9%) pts had mod-
erate renal insufficiency. Degree of renal insufficiency significantly correlated with 60-day
death and rehospitalization- severe 37.4%; moderate 33.4%; normal 18.2% (p <0.01).
There were 531 pts with BB and 377 pts without a BB on discharge. In a risk-adjusted
model, there was no adverse effect of BB use in patients with moderate or severe renal
insufficiency (wald chi-sqr =0.0748; p= 0.7845).
Conclusions: Beta-blockers may be safely used in HF patients with renal insufficiency.
Beta-blocker use does not appear to cause early worsening HF requiring rehospitaliza-
tion even in patients with moderate or severe renal insufficiency.
1012-121 Lack of Heart Rate Effects on the Mortality Benefits of 
Carvedilol Compared to Metoprolol in the Patients With 
Heart Failure: Results From the Carvedilol or Metoprolol 
European Trial (COMET)
Marco Metra, John G. Cleland, Andrea Di Lenarda, Peter Hanrath, Michel Komajda, 
Beatrix Lutiger, Philip A. Poole-Wilson, Willem J. Remme, Armin Scherhag, Andrew 
Charlesworth, Karl Swedberg, Christian Torp-Pedersen, For the COMET investigators, 
University of Brescia, Brescia, Italy, National Heart and Lung Institute, London, United 
Kingdom
Background: The Carvedilol or Metoprolol European Trial (COMET) has shown a reduc-
tion in all-cause mortality with carvedilol, compared with metoprolol, in 3029 patients with
chronic heart failure (RR 0.83, 95%CI, 0.74-0.93, p=0.0017). The potential influence on
this difference of effects on heart rate (HR) are unknown.
Methods: We related the effects on long-term mortality of baseline HR and early
changes (∆) of HR in COMET. Baseline analyses are presented for the intent to treat
population, ∆HR analyses are on treatment.
Results: At the end of uptitration, 4 months after randomization, mean HR declined from
baseline by 13.3 beats per minute (bpm) in the carvedilol group and 11.7 bpm in the
metoprolol group (difference -1.6 bpm; 95%CI, -2.7 to -0.6). Patients on carvedilol main-
tained a significantly lower mean HR only at two more visits (8, 16 months). Among the
2579 patients reassessed at 4 months, ∆ HR > -12 bpm (median value) was found in 714/
1289 (55%) patients on carvedilol and in 640/1290 (50%) patients on metoprolol
(p=0.0033). Compared with the others, the patients with a > -12 bpm ∆HR had a higher
baseline HR (87+13 versus 75+11 bpm, p<0.001) and a lower LVEF (25.6+7 versus
26.7+7% p<0.001) with a lower percentage of males (78% versus 82%, p=0.0082) and of
patients with a pacemaker (2.6% versus 9.1%; p<0.001) and a higher percentage in
sinus rhythm (78.5% versus 73.2%; p=0.0017). Within each subgroup, the HR profiles
were the same for carvedilol and metoprolol. Mortality was the same (31%) in the
patients with a ∆HR > or < -12 bpm. Mortality was reduced with carvedilol, compared to
metoprolol, both in the patients with ∆HR > -12 bpm (28% versus 35%; RR 0.77, 95% CI,
0.64-0.94; p=0.0086) and in the others (28% versus 34%; RR 0.79; 95% CI, 0.65-0.97;
p=0.0229). No interaction between the effect on mortality of carvedilol, compared to
metoprolol, and the ∆HR was found (RR 1.021; 95% CI, 0.77-1.35). By multivariate anal-
ysis, neither the baseline HR nor ∆HR were associated with mortality.
Conclusion: Outcome is not directly or simply related to baseline HR or its early
changes in COMET.
1012-122 Chronic Treatment With Carvedilol Improves Left 
Ventricular Pump Performance by Increasing Intrinsic 
Myocardial Contractility in Patients With Heart Failure
Biykem Bozkurt, Blase A. Carabello, Adrienne Chee, Suzanne Sorof, Douglas L. Mann, 
Veterans Affairs Medical Center, Houston, TX, Baylor College of Medicine, Houston, TX
Background: Chronic treatment with β-blockers improves LV pump performance in
patients with heart failure (HF); however, it is not known whether this improvement is
related to changes in LV remodeling, LV loading conditions or intrinsic myocardial con-
tractility. Accordingly, the purpose of this study was to study mechanisms of improve-
ment in LV pump performance following β-blocker treatment in HF patients. Methods: 32
patients with HF, LVEF<35 %, NYHA Class II-IV, on ACE inhibitors but not on β-blockers
were studied at baseline and at 6 months after treatment with carvedilol. Cardiac output
(CO), LV fractional shortening (FS), velocity of circumferential fiber shortening (VCF)- rel-
atively afterload dependent measures of contractility, LV end systolic stress
(LVESS),VCF:LVESS relation –an afterload corrected measure of contractility, LV end
diastolic volume (LVol), and LV mass (LVM) were measured by echocardiography and
LVEF by MUGA. Results: Carvedilol treatment resulted in significant (p 0.01-0.04)
improvements in load independent (VCF:LVESS ratio), and load dependent indices of
contractility (FS,VCF, LVEF), as well as a decrease in LV end-diastolic volume.(Table)
There were no significant changes in LV end-systolic stress or in LV mass. Conclusions:
Taken together these studies suggest that the improvements in LV pump performance
after chronic treatment with carvedilol are multifactorial and are related to changes in
intrinsic myocardial contractility as well as changes in LV preload.
